JP2016510748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510748A5 JP2016510748A5 JP2015561618A JP2015561618A JP2016510748A5 JP 2016510748 A5 JP2016510748 A5 JP 2016510748A5 JP 2015561618 A JP2015561618 A JP 2015561618A JP 2015561618 A JP2015561618 A JP 2015561618A JP 2016510748 A5 JP2016510748 A5 JP 2016510748A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- cancer
- alkyl
- linear
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772885P | 2013-03-05 | 2013-03-05 | |
| US61/772,885 | 2013-03-05 | ||
| PCT/US2014/020858 WO2014138279A1 (en) | 2013-03-05 | 2014-03-05 | Compounds for treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019017755A Division JP2019077727A (ja) | 2013-03-05 | 2019-02-04 | 癌の処置のための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510748A JP2016510748A (ja) | 2016-04-11 |
| JP2016510748A5 true JP2016510748A5 (enExample) | 2017-04-06 |
| JP6835472B2 JP6835472B2 (ja) | 2021-02-24 |
Family
ID=51491914
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561618A Expired - Fee Related JP6835472B2 (ja) | 2013-03-05 | 2014-03-05 | 癌の処置のための組成物 |
| JP2019017755A Pending JP2019077727A (ja) | 2013-03-05 | 2019-02-04 | 癌の処置のための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019017755A Pending JP2019077727A (ja) | 2013-03-05 | 2019-02-04 | 癌の処置のための組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10022356B2 (enExample) |
| EP (1) | EP2964028A4 (enExample) |
| JP (2) | JP6835472B2 (enExample) |
| KR (1) | KR102246652B1 (enExample) |
| CN (2) | CN105163584B (enExample) |
| AU (2) | AU2014225761B2 (enExample) |
| CA (1) | CA2904338C (enExample) |
| IL (1) | IL241232B (enExample) |
| MX (2) | MX375059B (enExample) |
| RU (1) | RU2708247C2 (enExample) |
| WO (1) | WO2014138279A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029408B2 (en) * | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| DK2959900T3 (en) * | 2008-06-16 | 2017-06-26 | Univ Tennessee Res Found | CONNECTION TO TREATMENT OF CANCER |
| US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| EP2964028A4 (en) | 2013-03-05 | 2017-06-07 | University of Tennessee Research Foundation | Compounds for treatment of cancer |
| ES2815374T3 (es) | 2014-05-06 | 2021-03-29 | Oncternal Therapeutics Inc | Compuestos para el tratamiento del cáncer |
| CN104434924B (zh) * | 2014-11-10 | 2016-09-14 | 暨南大学 | 曲美替尼在制备逆转肿瘤多药耐药性药物中的应用 |
| US20190117652A1 (en) * | 2014-12-23 | 2019-04-25 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and taxanes |
| WO2016130917A1 (en) * | 2015-02-12 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Synergistic cancer treatment |
| WO2016197129A1 (en) | 2015-06-05 | 2016-12-08 | The Board Of Trustees Of The University Of Illinois | Pac-1 combination therapy |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
| CA2991777A1 (en) * | 2015-07-09 | 2017-01-12 | The Jackson Laboratory | Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor |
| CA2995586A1 (en) * | 2015-08-06 | 2017-02-09 | The Wistar Institute Of Anatomy And Biology | Combination therapies targeting mitochondrial biogenesis for cancer therapy |
| JP6987084B2 (ja) | 2016-03-16 | 2021-12-22 | ディセルナ ファーマシューティカルズ インコーポレイテッド | β−カテニン関連疾患又は障害の治療のための組成物及び方法 |
| WO2017200826A1 (en) * | 2016-05-16 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Assays and compounds for treatment of cancer |
| AU2018209164B2 (en) | 2017-01-17 | 2021-11-04 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| JP7140103B2 (ja) * | 2017-03-10 | 2022-09-21 | コニカミノルタ株式会社 | 治療有効性の予測方法 |
| JP7291399B2 (ja) * | 2017-05-03 | 2023-06-15 | ティン セラピューティクス エルエルシー | 難聴の予防および治療のための組成物および方法 |
| AU2018368453B2 (en) | 2017-11-17 | 2024-05-30 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual MEK signaling |
| CN108218855A (zh) * | 2018-03-12 | 2018-06-29 | 桑文军 | 一种新型微管蛋白抑制剂及其在抗肿瘤药物中的应用 |
| AU2019270091A1 (en) * | 2018-05-15 | 2020-12-24 | University Of Tennessee Research Foundation | Compounds for treatment of pancreatic cancer |
| EP3793549A4 (en) * | 2018-05-15 | 2022-03-09 | University of Tennessee Research Foundation | COMPOUNDS FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER AND OVARIAN CANCER |
| KR20210084442A (ko) | 2018-10-05 | 2021-07-07 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 포도막 흑색종 치료를 위한 병용 요법 |
| GB201913124D0 (en) | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
| JP2023513015A (ja) * | 2020-01-31 | 2023-03-30 | ベラステム・インコーポレーテッド | 異常な細胞成長を処置するための併用療法 |
| CN113440616A (zh) * | 2020-03-25 | 2021-09-28 | 上海科州药物研发有限公司 | Ras或raf突变型癌症的联合疗法 |
| US20230355581A1 (en) * | 2020-07-02 | 2023-11-09 | The Board of Regents of the Unversity of Texas System | Methods of treatment for melanoma |
| WO2022067185A1 (en) * | 2020-09-27 | 2022-03-31 | Veru Inc. | Methods of treating prostate cancer with minimal side effects |
| WO2022131667A1 (ko) * | 2020-12-18 | 2022-06-23 | 경희대학교 산학협력단 | Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물 |
| CN115504964A (zh) * | 2022-04-12 | 2022-12-23 | 海创药业股份有限公司 | 氘代杂环酮类化合物及其用途 |
| CN117143081B (zh) * | 2022-05-24 | 2025-08-01 | 赣南医科大学 | 一种Sabizabulin的制备方法 |
| WO2024036114A2 (en) * | 2022-08-08 | 2024-02-15 | The Regents Of The University Of California | Combination therapy including cox-2 inhibitor for the treatment of cancer |
| WO2024186641A1 (en) * | 2023-03-03 | 2024-09-12 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| CN119409641A (zh) * | 2024-11-05 | 2025-02-11 | 杭州电子科技大学 | 一种磺酰基衍生物和用途 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601675B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| TW311136B (enExample) | 1990-11-30 | 1997-07-21 | Otsuka Pharma Co Ltd | |
| US5120749A (en) | 1991-02-20 | 1992-06-09 | Abbott Laboratories | Platelet activating antagonists |
| JP2550915B2 (ja) | 1994-06-21 | 1996-11-06 | 日本電気株式会社 | 印刷配線板の表面保護剤および表面保護膜の形成方法 |
| ES2257461T3 (es) | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
| WO2003027105A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Substituted 3-pyridyl thiophenes as c17,20 lyase inhibitors |
| US20040267017A1 (en) | 2001-09-26 | 2004-12-30 | Bierer Donald E | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors |
| FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
| WO2003043998A1 (en) | 2001-11-15 | 2003-05-30 | Incyte San Diego Incorporated | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
| EP1594847A2 (en) | 2003-02-12 | 2005-11-16 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
| ATE363905T1 (de) | 2003-04-17 | 2007-06-15 | Janssen Pharmaceutica Nv | 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5)- pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs |
| US20040248957A1 (en) | 2003-05-16 | 2004-12-09 | Ambit Biosciences Corporation | Heterocyclic compounds and uses thereof |
| WO2005049591A1 (en) | 2003-11-18 | 2005-06-02 | University Of Tennessee Research Foundation | Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof |
| AU2004298486A1 (en) | 2003-12-12 | 2005-06-30 | Wyeth | Quinolines useful in treating cardiovascular disease |
| CN1938023A (zh) | 2004-03-08 | 2007-03-28 | 惠氏公司 | 离子通道调节剂 |
| EP2298292A3 (en) | 2004-06-18 | 2011-08-10 | Agennix USA Inc. | Kinase inhibitors for treating cancers |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| DK2395004T3 (en) * | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| US7612212B2 (en) * | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
| US20090239936A1 (en) * | 2006-05-15 | 2009-09-24 | Yoshikazu Sugimoto | Prophylactic and Therapeutic Agent for Cancer |
| US7464893B2 (en) * | 2006-06-30 | 2008-12-16 | Per Spjut | Method of using a cord holder |
| KR100932093B1 (ko) | 2006-09-27 | 2009-12-16 | 주식회사종근당 | 미세소관 형성 저해제로서 유용한 벤조페논 유도체 |
| US8822513B2 (en) * | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| US9029408B2 (en) * | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| US9447049B2 (en) * | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| DK2959900T3 (en) | 2008-06-16 | 2017-06-26 | Univ Tennessee Res Found | CONNECTION TO TREATMENT OF CANCER |
| ES2745479T3 (es) | 2009-10-16 | 2020-03-02 | Novartis Ag | Combinación que comprende un inhibidor de MEK y un inhibidor de B-raf |
| CN102883607B (zh) * | 2010-03-01 | 2015-07-22 | Gtx公司 | 用于治疗癌的化合物 |
| US8426418B2 (en) | 2010-08-27 | 2013-04-23 | CollabRx Inc. | Method to treat melanoma in BRAF inhibitor-resistant subjects |
| KR101418229B1 (ko) | 2011-03-29 | 2014-07-09 | 미쓰비시덴키 가부시키가이샤 | 서보 제어 장치의 이상 진단 장치 및 이상 진단 시스템 |
| WO2012135759A1 (en) * | 2011-04-01 | 2012-10-04 | Genentech, Inc. | Combinations of akt inhibitor compounds and abiraterone, and methods of use |
| PL2694510T3 (pl) | 2011-04-07 | 2016-03-31 | Bayer Ip Gmbh | Imidazopirydazyny jako inhibitory kinazy Akt |
| EP2964028A4 (en) | 2013-03-05 | 2017-06-07 | University of Tennessee Research Foundation | Compounds for treatment of cancer |
-
2014
- 2014-03-05 EP EP14760577.8A patent/EP2964028A4/en not_active Withdrawn
- 2014-03-05 MX MX2015011713A patent/MX375059B/es active IP Right Grant
- 2014-03-05 US US14/773,265 patent/US10022356B2/en active Active
- 2014-03-05 CN CN201480025267.4A patent/CN105163584B/zh active Active
- 2014-03-05 CN CN201811371741.5A patent/CN109568312A/zh active Pending
- 2014-03-05 CA CA2904338A patent/CA2904338C/en active Active
- 2014-03-05 WO PCT/US2014/020858 patent/WO2014138279A1/en not_active Ceased
- 2014-03-05 AU AU2014225761A patent/AU2014225761B2/en not_active Ceased
- 2014-03-05 KR KR1020157027404A patent/KR102246652B1/ko not_active Expired - Fee Related
- 2014-03-05 JP JP2015561618A patent/JP6835472B2/ja not_active Expired - Fee Related
- 2014-03-05 RU RU2015142102A patent/RU2708247C2/ru active
-
2015
- 2015-09-04 MX MX2020009256A patent/MX2020009256A/es unknown
- 2015-09-06 IL IL241232A patent/IL241232B/en active IP Right Grant
-
2018
- 2018-07-12 US US16/033,953 patent/US10525037B2/en active Active
- 2018-09-06 AU AU2018226470A patent/AU2018226470B2/en not_active Ceased
-
2019
- 2019-02-04 JP JP2019017755A patent/JP2019077727A/ja active Pending